The FDA review – which is due to be completed by 28th September – revolves around the results of the HERCULES trial which ...

Novartis’ oral Fabhalta (iptacopan) has been approved by the US Food and Drug Administration (FDA) as the first treatment for ...

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the ...

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due ...